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WHAT THIS PAPER ADDS 
The literature is full of papers examining outcomes for different types of stent grafts for repairing 
infrarenal abdominal aortic aneurysms. New stent grafts are released regularly with publications 
ƌepoƌtiŶg theiƌ ͞safetǇ͟ oƌ supeƌioƌitǇ, ďut theƌe is Ŷo ĐoŶseŶsus oŶ hoǁ to ƌepoƌt this. There is also 
no information on how many patients would be needed to prove non-inferiority to accepted devices. 
This is the first time that individual EVAR stent graft complication rates have been pooled in meta-
analysis, a consensus performed, then the numbers of patients required for registry publications 
calculated from the results. 
Objectives: New and re-designed stent grafts for endovascular aortic aneurysm repair (EVAR) are 
released regularly. Manufacturers use data from registries to assess stent graft performance, but little 
is known about the ability of such registries to detect rates of clinically relevant complications. The 
aim of this paper was to perform a systematic review and meta-analysis to determine pooled failure 
rates for EVAR stent grafts, to define an acceptable non-inferiority limit for these devices, and then to 
calculate the number of patients needed for a new device to achieve non-inferiority against published 
devices. 
Data sources and review methods: MEDLINE and EMBASE were searched for studies reporting 
outcomes of specific EVAR grafts being used for intact infrarenal abdominal aortic aneurysms, from 
inception to November 2016. Meta-regression was performed to pool data and calculate the patient 
numbers needed to detect noninferiority of a future graft performance. An expert consensus was 
performed to define adequate standards for device safety. 
Results: One hundred and forty-seven moderate quality papers involving 27,058 patients were 
included. Multiple outcomes were pooled. Of these, the estimated rate (standard error) of overall 
endoleak (excluding Type II) at 2 years was 5.7  0.6%.The pooled re-intervention rate was 11.1  0.7% 
at 2 years.There were differences in pooled endoleak rates between different stent graft types. Expert 
consensus defined non-inferiority as better performance than the worst performing 25% of stent 
grafts.The most popular outcome in the expert consensus was cumulative endoleak rate (excluding 
Type II). The number of patients who would need to be enrolled in a registry to demonstrate non-
inferiority at this level was 525. Only two of 147 included studies achieved this. The second most 
popular choice in the expert consensus was re-intervention rate; 492 patients are required to 
demonstrate this.  
Conclusions: Five hundred and twenty-five patients need to be entered into a registry to demonstrate 
noninferiority to previous stent grafts. Almost all previous publications have captured lower patient 
numbers. With performance varying between devices, and new devices being introduced regularly, 
there is an urgent need to capture higher quality long-term data on EVAR stent grafts. 
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INTRODUCTION 
The incidence of abdominal aortic aneurysm (AAA) repair continues to increase in the western world.1 
Around 40,000 non-ruptured AAA are treated every year in the United States alone, with 80% being 
treated endovascularly. In the UK the proportion of AAA treated endovascularly has increased from 
less than 10% in 2005 to around 60% in 2012, and continues to grow.1 An infrarenal stent graft for 
endovascular AAA repair (EVAR) costs around $7000.2 
This creates a lucrative market for device manufacturers, and new stent grafts for performing EVAR 
are released regularly. Commonly used, established stent grafts are given regular iterative updates, 
which often retain the same name for marketing purposes but may alter the graft design and 
structure.3,4 The regulatory requirements for stent graft use vary by country or territory, and while 
not always available for scrutiny comprise a mixture of bench testing and limited clinical data. The 
͞safetǇ͟ aŶd ŵaƌketiŶg data foƌ these deǀiĐes is theƌefoƌe usuallǇ ďased oŶ post-market surveillance 
registry publications; a recent Cochrane review highlighted that no randomised trials exist comparing 
one stent graft type with another.5 Stent graft fixation, material, and stent design all vary between 
manufacturers, and different devices have appeared to suffer from different types of failure 
historically.6 Most devices fail after more than 5 years, meaning long-term follow-up of EVAR stent 
grafts is especially important. 
These device failures lead to a significant late complication rate after EVAR, which includes treated 
AAAs rupturing, often leading to death.7 Even though there is a perception that individual stent graft 
designs failed in different ways, these results have never been pooled and compared. The ability of 
stent graft registry publications to detect failures that could lead to patient death is unknown. Exactly 
which of these late failures is of most interest to surgeons and radiologists is also undefined. The aims 
of this paper were therefore threefold: 
1. To perform a systematic review and meta-regression todetermine pooled failure rates for 
EVAR stent grafts. As part of this process, to examine individual factors leading to stent graft failure 
where available. 
2. To define an acceptable non-inferiority limit for EVAR stent grafts via expert survey. 
3. To calculate the number of patients needed for a newdevice registry to achieve non-inferiority 
against previous devices. 
MATERIALS AND METHODS 
Systematic review and meta-regression 
Search methods. A systematic review of published work was conducted as per the protocol specified 
by the Cochrane collaboration,8 and reported in line with the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) statement for the conduct of meta-analyses of intervention 
studies.9 The following sources were searched: Medline via PubMed, Embase, and the Cochrane 
Library Database (Cochrane Central Register of Controlled Trials) for studies comparing stent graft 
types for endovascular repair of intact abdominal aortic aneurysms (AAAs). All studies describing 
results from more than 10 patients were included. Non-English language papers were excluded. 
Studies arising from duplicate publications and review articles were excluded. Studies were excluded 
if the subjects included non-degenerative AAAs, thoracic, thoraco-abdominal, or isolated iliac 
aneurysms. Studies of only emergency or complex aneurysms (fenestrated, extreme anatomy, e.g. 
angled neck, short neck) were excluded, though if these were case cohort studies, data from the 
control group (non-emergency, non-complicated) were extracted. Studies of endovascular sealing 
devices were excluded. As a result, stent grafts (and manufacturers) included were Zenith (Cook 
Medical, Bloomington, IN, USA); Zenith Low Profile (Cook Medical); Endurant (Medtronic, 
Minneapolis, MN, USA); Excluder (W.L. Gore, Newark, DE, USA); AFX (Endologix, Irvine, CA, USA); 
Anaconda (Vascutek, Inchinnan, Glasgow, UK); Aorfix (Lombard, Didcot, UK); Powerlink (LeMaitre, 
Burlington, MA, USA); Talent (Medtronic); AneuRx (Medtronic); Incraft (Cordis, Milpitas, CA, USA). For 
each stent graft the headiŶg ͞AŶeuƌǇsŵ͟ aŶd the speĐifiĐ steŶt gƌaft Ŷaŵe, e.g. ͞EǆĐludeƌ͟, ǁeƌe used 
as search terms. 
Articles were also identified by hand searching of references and extensive use of the related articles 
function in PubMed. The last search date was November 24, 2016. 
Data extraction. Data were extracted independently by two authors (F.K. and D.B.). Data extraction 
was initially trialled on 10 papers, and then refined. Extracted demographic data included stent graft 
studied, company sponsored study, onor off label use, years over which graft studied, study design, 
number of patients, and duration of follow-up. 
Outcome data collected included endoleak rates and types, re-intervention rates, and late rupture 
rates. Data on Type IV and V endoleaks were initially collected, but due to the extremely low reported 
rates of Type IV leaks, and the heterogeneity inherent in Type V leak definition, results for these types 
of leaks were not further examined, though they are pooled within total cumulative endoleak rates. 
Study quality was assessed using the NewcastleeOttawa scale.10 Further details of extracted data are 
given in Appendix 1. Where short and long-term results from the same patient cohort were published 
separately, relevant data were retrieved from both publications preferentially using the latest. 
Statistical analysis 
Type I-III endoleaks were modelled using weighted linear regression modelling, with constant term 
ƌepƌeseŶtiŶg iŶitial ͞failuƌe to seal͟ aŶd liŶeaƌ teƌŵ ƌepƌeseŶtiŶg suďseƋueŶt deǀelopŵeŶt of leak 
over time: leak rate ¼ late leak rate  mean follow-up time þ failure to seal. 
Terms were weighted in the regression analysis according to the number of patients in the study. 
Overall endoleak rates, re-intervention rates, and rupture rates were modelled in the same way. The 
reason that meta-regression was chosen over fixed point meta-analysis was that different studies 
included different follow-up times, so attempting to consider these rates at one or more time points 
ǁould haǀe ŵeaŶt disĐaƌdiŶg aŶ eŶoƌŵous aŵouŶt of the puďlished data. Negatiǀe ͞failuƌe to seal͟ 
estimates were set to zero. Confounder adjustment was performed using multivariate linear 
regression for mean patient age, proportion of male patients and mean aneurysm diameter if these 
teƌŵs ǁeƌe sigŶifiĐaŶt ďased oŶ ĐalĐulatioŶ of Akaike’s IŶfoƌŵatioŶ CƌiteƌioŶ. Akaike’s IŶfoƌŵatioŶ 
Criterion (AIC) is a standard statistical tool for model selection. The AIC penalises complex models, so 
minimisation of AIC is a way of ensuring that predictors that improve the fit of a model more than they 
increase its complexity are included. Separate regression models were also fitted for graft types with 
data from at least 10 studies. R (https://www.r-project. org) was used for all statistical analysis. 
Definition of non-inferiority 
Expert survey. No formal guidance exists to define inferiority of endovascular devices. Numerous 
outcomes could potentially be selected when comparing new endografts with existing products. 
Furthermore, how non-inferiority should be defined (in terms of deviation from previously published 
outcome rates) has not previously been stipulated. 
In order to decide how to define clinically significant failure rates for use in determining the 
appropriate sample size for a new device registry, medical members of the British Society for 
Endovascular Therapy (BSET) Council (https://www.bset.co.uk/about-bset/council-members) were 
surveyed for a consensus. The survey was pre-defined using feedback and iteration by the authors and 
the research subcommittee of BSET. The council includes high volume EVAR practitioners (surgeons 
and radiologists) and actively publishing EVAR academics. The council were asked what statistical 
definition of non-inferiority should be used for a power calculation, and what they felt was the most 
relevant complication of EVAR stent grafts on which to base that calculation. The questionnaire was 
performed before any analyses. The full survey, with multiple choice options and answers, is given in 
Supplementary Table I. 
Number of patients needed to achieve non-inferiority in new studies 
Statistical analysis. A Bayesian approach was used to investigate the number of patients required in 
a registry for a new device to detect leak, re-iŶteƌǀeŶtioŶ, oƌ late ƌuptuƌe ƌates ;͞ƌates͟Ϳ ǁhiĐh ǁeƌe 
iŶfeƌioƌ ďǇ a defiŶed, ͞ĐliŶiĐallǇ sigŶifiĐaŶt͟ ƋuaŶtitǇ e deteƌŵiŶed ďǇ the eǆpeƌt suƌǀeǇ. Rates ǁeƌe 
modelled using a Beta prior,16 with parameters estimated from the meta-regression above. A binary 
search strategy was then used to find the number of patients for a new registry which would be 
required, under this model, to show inferior rates with 80% power determined by the predefined 
͞ĐliŶiĐallǇ ƌeleǀaŶt͟ ƌate. These patieŶt Ŷuŵďeƌs ǁere calculated for 2 and 5 years of follow-up using 
a Monte Carlo technique. 
Attrition rates for EVAR treated patients were needed to adjust the numbers of patients required for 
entry into a registry to produce enough patients at 2 and 5 years to detect late complications. This 
length of time was chosen based on previous randomised data picking up the majority of early 
complications in this timeframe. Rates were calculated by pooling attrition rates for the EVAR arms of 
all randomised control trials on EVAR versus open repair or conservative management for AAA,11e15 
as these were felt to be more likely to accurately reflect true attrition rates with high quality follow-
up than cohort studies. 
RESULTS 
Systematic review and meta-regression 
Literature search and study characteristics. Database searches identified 1584 unique studies and 
searching through references revealed 17 further studies (Fig. 1). A total of 1601 abstracts were 
screened and 213 full articles were obtained. One hundred and forty-seven papers involving 27,058 
patients were included in analysis. This included no randomised controlled trials (RCTs), 22 
registries/Phase II clinical trials, 46 cohort studies, and 79 case series. Seventy (48%) studies were 
prospective. The median NewcastleeOttawa score was 4 (range 3e8; Supplementary Table II). The 
weighted mean follow up was 24 months (range 1e120 months), and the median patient number 
enrolled on the studies was 111 (IQR 49e214). The pooled mean patient age was 73 years, and 89% of 
patients were male. The mean aneurysm diameter was 57 mm. Full details of all included studies are 
given in Supplementary Table II. 
Fifteen per cent were company funded registries and 22% of the remaining papers declared company 
sponsorship. The median patient number enrolled on company sponsored registries was significantly 
larger (236, IQR 80e357) than non-company sponsored registries (100, IQR 44e178; 
 Figure 1. Identification process for eligible studies. 
P=0.001), although the median follow up was shorter (12, IQR 8e22, vs. 22, IQR 12e36; p ¼ .01). 
Company sponsorship had no relationship to endoleak (p ¼ .77) or reintervention rates (p ¼ .22). 
Thirty-seǀeŶ peƌ ĐeŶt of studies iŶĐluded oŶlǇ patieŶts tƌeated aĐĐoƌdiŶg to the ŵaŶufaĐtuƌeƌ’s 
instructions for use (IFU). 
The weighted mean attrition rate from all included studies at 30 days was 2%. By 1 year it was 29%. 
The attrition rate from EVAR RCTs was lower than this at 1.9% and 8.5% respectively. 
Endoleak rates. Table 1 shows pooled results from metaregression after EVAR. Type I, II, and III 
endoleak rates (standard error) at 2 years were 3.4  0.3%, 13.0  1.0%, and 0.8  0.1% respectively. The 
overall endoleak rate at 2 years was 18.9  1.2%, and was 5.7  0.6% when Type II endoleaks were 
excluded. Fig. 2 shows the fitted regression model for overall endoleak rate (excluding Type II) and 
shows weighting by study size and stent graft type. 
Graft specific outcomes. Six grafts (Zenith, Talent, Endurant, Excluder, Anaconda and AneuRx) had 
data from at least 10 separate studies (23, 24, 23, 28, 10, and 21 respectively). Zenith could not be 
subdivided into Zenith and Zenith Low Profile (LP) because of the 23 studies (5754 patients) reporting 
on Zenith, only one19 included a cohort with Zenith LP (101 patients). Endurant could also not be 
subdivided in this way: of 25 studies (4783 patients), only one study reported outcomes from Endurant 
II (64 patients),20 and there were no studies of the current Endurant IIs. 
Predicted endoleak, re-intervention, and late rupture rates at 2 years for the different grafts are given 
in Table 1. Stent grafts performed significantly differently. For example the Endurant graft from 
Medtronic performed significantly better for cumulative endoleak rate (excluding Type II) than its 
predecessor the Talent graft, with rates of 3.5  1.2% vs. 8.4  1.6% (p< .01) respectively. 
 
 
 
Records identified through  
database searching 
(n=1584) 
Records identified through other  
sources 
(n=17) 
Records screened by abstract 
(n=1601) 
Records excluded as no data on  
EVAR 
(n=1388) 
Full text assessed for eligibility 
(n=213) 
Records excluded 
(n=66) 
No relevant data n=53 
Mix of EVAR and open n=5 
Open AAA n=3 
Review only n=3 
FEVAR=2 
Studies included in meta-analysis 
(n=147) 
Table 1. Results of pooled meta-regression 
 
 
 
 
 
Type I 
endoleak 
 Total 
no. of 
patient
s 
 Numbe
r 
of 
studies 
 Mean 
follow 
up 
time 
(years
) 
 Estimate
d rate at 
2 years’ 
follow-
up (%) 
 Standar
d error 
 Adjuste
d R2 
 Numbers 
needed to show 
non-inferiority 
 2 
year
s 
 5 years 
 17,068 106 2.10 3.39 0.29 0.24 903 1190 
Type II 
endoleak a 
 17,900  110  1.84  13.04  0.96  0.04  298  278 
Type III 
endoleak 
16,116 98 1.87 0.76 0.13 0.25 964 1597 
Cumulative 
endoleak 
 16,035  104  2.09  18.86  1.23  0.09  225  212 
Cumulative 
endoleak rate 
excluding Type 
II 
13,636 89 1.88 5.67 0.55 0.28 525 720 
Re-
interventio
n rate b 
 21,595  126  2.26  11.12  0.68  0.23  492  500 
Re-
intervention 
for Type II 
15,586 101 2.05 3.08 0.28 0.15 970 1273 
Late 
rupture c 
 20,999  100  2.13  0.60  0.07  0.20  2773  3759 
Note. Numbers in the final two columns are the number of patients needing to be entered into a 
registry to show non-inferiority for the stated outcome. Numbers needed to show non-inferiority have 
been adjusted to allow for attrition rates similar to those seen in randomised controlled trials, which 
were 17% at 2 years and 41% at 5 years. 
a Adjusted for the proportion of male patients. 
b Adjusted for median patient age and mean aneurysm size. 
c Adjusted for mean aneurysm size. 
 
 
 
Definition of non-inferiority 
Expert survey. Thirteen responses from 16 polled experts were received. All of these responded to 
both questions. The majority (7 respondents) felt that a new device could be declared non-inferior if 
the registry were large enough to show with reasonable power that complication rates were at least 
as good as those pooled from 75% of existing devices.  Regarding the most important outcome for 
ĐalĐulatiŶg saŵple size, fiǀe ƌespoŶdeŶts seleĐted ͞eŶdoleak ƌate eǆĐludiŶg TǇpe II eŶdoleaks͟, fouƌ 
ƌespoŶdeŶts seleĐted ͞ƌeiŶteƌǀeŶtioŶ ƌates͟, ǁhile tǁo thought ͞TǇpe I eŶdoleak ƌate͟ ǁas ŵost 
important. Full results are given in Supplementary Table I. 
 
 
Figure 3. Bubble plot showing fitted meta-regression model for reintervention rate 
 
 Number of patients needed to achieve non-inferiority in new studies 
The number of patients required for a registry to detect non-inferiority for total endoleak rate 
(excluding Type II) was calculated as 525 patients at 2 years, taking attrition rates into account (Table 
1). Only two of the 147 studies (1.4%) published in the literature17,18 had sufficient numbers of 
patients and duration of follow-up to satisfy the requirements of the expert survey.   
Re-intervention and rupture rates. The second most popular choice in the expert consensus was re-
intervention rate. This was 11.1  0.7% at two years, of which 3.1  0.3% was for Type II endoleak. Four 
hundred and ninety-two patients would be required to detect noninferiority for re-intervention rates 
at 2 years. Fig. 3 shows the fitted regression line for re-intervention rates as well as data from the 
available studies and shows weighting by study size and stent graft type. 
Late rupture rates were 0.6  0.1% at 2 years. Far larger numbers would be needed for a registry to 
detect late rupture rates; 2773 patients would need to be enrolled in order to show non-inferiority for 
late rupture at 2 years. None of the included studies enrolled patient numbers this large. 
DISCUSSION 
This study has shown that 525 patients are required for a registry to show acceptable non-inferiority 
at 2 years for new or altered EVAR stent grafts at the consensus level. Only two of 147 studies in the 
literature met this retrospective requirement.17,18 One was a company sponsored registry.17 Both 
of these stent grafts have subsequently been redesigned to be mounted on low profile delivery 
devices, which means although they are marketed under similar names they differ in both stent and 
graft material design. Neither of the re-designs have publications with enough patients to satisfy the 
non-inferiority definition. 
To put the primaryoutcome measure of non-inferiority into context, cumulative endoleak rate 
(excluding Type II) means that all graft related failures (Type, I, III, IV, and V endoleaks) are included. 
Type II endoleaks are thought to be patient related and therefore representative of patient selection 
rather than the stent graft itself.21 Type II endoleaks are also more variably detected and reported, 
intervened for, and are thought to be less clinically relevant than the others.22 This perception is 
reinforced by cumulative endoleak (excluding Type II) having the best fit of all meta-regression models 
run (Table 1; adjusted R2 ¼ 0.28). The model fit improved significantly (0.09e0.28) when Type II 
endoleak was removed, and the fit for Type II endoleak re-intervention was relatively poor (0.15), 
further implying agreement. Stent graft limb occlusion rates could also be included in a composite 
endpoint like this; however, they are also variably re-intervened for, and almost never lead to patient 
death.The numbers needed for patients to define safety by different endoleak types including Type II 
are included in Table 1. 
Attrition rates were particularly high in these studies. This is highlighted by the 29% pooled attrition 
rate at 1 year. This compares badly to the EVAR arms of RCTs, and even to the EVAR 2 trial (21% 
attrition at 1 year), which included medically unfit patients and had a higher mortality than RCTs of 
representative AAA patients.11 Attrition in the included studies is therefore likely to have poor follow-
up, which needs addressing in future registries. The other concern is that the high attrition rates will 
mask higher stent graft failure rates than those found at 1 year. This is a problem with the EVAR and 
aneurysm literature in general, and can only be compensated for by more robust follow up regimens. 
The importance of follow up after EVAR has recently been highlighted by the late results of the EVAR 
1 randomised trial, which randomised patients fit for open repair to either that or EVAR. This has 
shown a significant late (>5 years) complication rate in the EVAR arm, to the extent where the initial 
survival benefit in the EVAR arm was reversed at 8 years.7 Although stent graft designs have changed 
over this time, and complications reduced (Table 2), length of follow-up remains a concern, especially 
as the median follow-up from these data was only 24 months. Pragmatically, the cost of entering 
enough patients and maintaining registries for between 5 and 10 years makes this unlikely, but other 
data sources should be considered. For example, the National Vascular Registry in the UK captures 
data on all EVARs performed in the UK, and stent graft type could easily be added as a field.23 
Registries can be powerful for detecting device related complications as shown by the metal on metal 
hip implant scandal which was first detected by the National Joint Registry of England and Wales.24,25 
This is urgently required for EVAR stent grafts as different designs performed significantly differently 
from one another in the analysis when comparing graft related endoleaks, and national registries 
which do not routinely capture anatomical considerations and linked endoleak/re-intervention rates 
should consider doing so. Table 2. Graft specific endoleak, re-intervention and late rupture rates for 
the six grafts with data from at least 10 studies 
 
 
 
 
 
 
 
Table 2. Graft specific endoleak, re-intervention and late rupture rates for the six grafts with data from 
at least 10 studies 
 
 
 
 
 
Zenith 
Type I 
endoleak 
Type II 
endoleak 
Type IIII 
endoleak 
Cumulative 
endoleak 
Cumulative 
endoleak 
rate 
excluding 
Type II 
Re-
intervention 
rate 
Re-
intervention 
for Type II 
Late 
rupture 
 3.5  0.6 17.9  1.8 0.9  0.3 25.9  2.8 5.7  1.2 11.6  1.8 4.7  0.6 0.9  0.2 
Talent 5.3  0.8 10.8  2.1 1.1  0.4 18.4  3.5 8.4  1.6 11.9  1.7 2.3  0.7 0.8  0.2 
Endurant 1 2.0  0.6 11.3  2.0 0.5  0.3 11.7  3.2 3.5  1.2 9.5  1.9 2.3  0.6 0.3  0.2 
Excluder 2.5  0.7 11.6  2.1 0.1  0.3 23.0  3.9 7.0  1.8 10.2  1.8 3.1  0.7 0.4  0.2 
Anaconda 2.2  1.0 14.8  3.0 0.5  0.5 15.1  4.1 3.4  1.8 8.7  3.5 0.8  1.3 0.4  0.3 
AneuRx 6.1 0.9 11.9 2.4 2.4 0.5 19.2 3.7 8.7 1.7 15.4 1.5 4.2 0.8 0.7 0.2 
 
Study quality was poor in this field but could be improved in the future by powering studies using the 
numbers in this analysis, more thorough follow-up regimens, and improved data collection. There was 
also significant variability in outcome reporting between studies, so future datasets could be 
standardised using the outcomes reported here. Aneurysm related survival could also be reported, 
but would need a huge number of patients to have any power to detect poor performance, and is 
difficult to collect outside a randomised control trial. The survey was predefined by a consensus, but 
a larger (e.g., Delphi) process would have made it more robust. 
Because of a lack of reporting within studies, data could not be adjusted or analysed by adherence to 
the ŵaŶufaĐtuƌeƌ’s IFU. This ǁould haǀe been interesting because adherence to the IFU is known to 
produce better clinical results.26 However, in real world studies only 30e70% of stent grafts are 
actually inserted in anatomy adhering to IFU,27 so this analysis remains a valid, pragmatic 
representation of the use of stent grafts during EVAR. It was impossible to subdivide grafts by iterative 
updates under the same or a similar name because the current generation of updated grafts had too 
few data available. 
The definition of non-inferiority used was from an expert consensus, but it is acknowledged that there 
are many other ways to define non-inferiority in this setting; there is no standard. For that reason, 
analyses are included which would allow other researchers to calculate patient numbers based on 
other definitions of non-inferiority. This would potentially range from 225 to 2773 patients depending 
on the outcome of choice. The consensus was taken before analysis but examining the results the 
outcome chosen appears reasonable; the regression model fit was the best for this outcome and the 
number of patients needed to power was between the lowest and highest for other outcomes.   
 
 
CONCLUSION 
Five hundred and twenty-five patients need to be entered into a registry to demonstrate non-
inferiority to previous stent grafts for EVAR in a 2 year time period. Current registries had serious 
limitations, with only 1% of included studies including enough patients. With performance varying 
between devices, and the majority of grafts included in this analysis now being last generation, there 
is an urgent need to capture higher quality long-term data on EVAR stent grafts. 
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Appendix 1 
Extracted data. 
Study design Cohort and graft 
characteristics  
Baseline 
demographics and 
patient factors 
(number of patients 
unless stated)  
Outcomes (number 
of patients unless 
stated) 
Type of study 
(RCT/cohort/case series) 
Number of patients Age (median/mean) Length of procedure 
in minutes 
(mean/median) 
Data analysis 
(retrospective/prospective) 
Graft type  Sex   Endoleak rate 
(separate for each 
Types IeIII) 
Company sponsored 
(yes/no)  
Company  ASA (median) Total endoleak rate 
Publication year Graft generation
  
Aneurysm width Total re-intervention 
rates 
Midpoint of study year Graft used on IFU 
(yes/no) 
Follow up time 
(mean/median) 
 
Late rupture rate 
Ruptures included (yes/no)    
Newcastle Ottawa Score    
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